GLYCOTEST

Glycotest Diagnostics is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for groups at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease. Over 25 million people in the US, 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease may benefit from Glycotest’s products.